R-PMDT Regimen in Newly Diagnosed PCNSL

A total of six cycles of the R-PMDT regimen (rituximab, pirtobrutinib, high-dose methotrexate, dexamethasone, and thiotepa) will be administered to patients with newly diagnosed primary central nervous system lymphoma (PCNSL). The primary objective is to assess the overall response rate (ORR) of R-PMDT. Secondary objectives include evaluating the complete response rate, progression-free survival (PFS), overall survival (OS), and safety.

NCT Number	NCT07604987
Lead Sponsor	Zou Dehui
Conditions	Primary Central Nervous System (CNS) Lymphoma
Enrollment	33 participants
Start Date	2026-05-20
Primary Completion	2028-05-20 (estimated)
Study Completion	2030-05-20 (estimated)
Updated on ClinicalTrials.gov	2026-05-22